Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
116 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Review, H1 2016', provides in depth analysis on C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted pipeline therapeutics. The report provides comprehensive information on the C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - The report reviews C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics and enlists all their major and minor projects - The report assesses C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) Overview 10 Therapeutics Development 11 C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Products under Development by Stage of Development 11 C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Products under Development by Therapy Area 12 C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Products under Development by Indication 13 C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Pipeline Products Glance 16 Late Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Products under Development by Companies 19 C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Products under Development by Universities/Institutes 24 C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Therapeutics Assessment 26 Assessment by Monotherapy/Combination Products 26 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Companies Involved in Therapeutics Development 33 AdAlta Pty Ltd. 33 Ambrx, Inc. 34 Anchor Therapeutics, Inc. 35 Biokine Therapeutics Ltd. 36 BioLineRx, Ltd. 37 Bristol-Myers Squibb Company 38 Eli Lilly and Company 39 Globavir Biosciences, Inc. 40 GlycoMimetics, Inc. 41 NeED Pharma s.r.l. 42 Pharis Biotec GmbH 43 Polyphor Ltd. 44 Sanofi 45 TaiGen Biotechnology Co., Ltd. 46 Upsher-Smith Laboratories, Inc. 47 X4 Pharmaceuticals, Inc. 48 C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Drug Profiles 49 (filgrastim + plerixafor) - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 ALB-408 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 AM-3114 - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 ATI-2341 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 balixafortide - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 BKT-170 - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 BL-8040 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 burixafor - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 GBV-4086 - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 GMI-1359 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 hz-515H7 - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 LY-2510924 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 Monoclonal Antibody Conjugate to Antagonize CXCR4 for Oncology - Drug Profile 75 Product Description 75 Mechanism Of Action 75 R&D Progress 75 Monoclonal Antibody to Antagonize CXCR4 for Breast Cancer - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 ND-4043 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 plerixafor - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 POL-5551 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Protein to Inhibit CXCR4 for Inflammation - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 PTX-9908 - Drug Profile 83 Product Description 83 Mechanism Of Action 83 R&D Progress 83 Q-122 - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 Recombinant Protein to Agonize CXCR4 for Multiple Sclerosis - Drug Profile 86 Product Description 86 Mechanism Of Action 86 R&D Progress 86 Recombinant Proteins to Antagonize CXCR4 for Oncology and Autoimmune Disorders - Drug Profile 87 Product Description 87 Mechanism Of Action 87 R&D Progress 87 Small Molecules to Activate CXCR4 for Immunology and Oncology - Drug Profile 88 Product Description 88 Mechanism Of Action 88 R&D Progress 88 Synthetic Peptide to Target CXCR4 and SDF-1 for HIV - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 ulocuplumab - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 USL-311 - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 X-4P001 - Drug Profile 93 Product Description 93 Mechanism Of Action 93 R&D Progress 93 X-4P002 - Drug Profile 95 Product Description 95 Mechanism Of Action 95 R&D Progress 95 C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Dormant Projects 96 C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Discontinued Products 101 C-X-C Chemokine Receptor Type 4 (Fusin or Leukocyte-Derived Seven Transmembrane Domain Receptor or Lipopolysaccharide-Associated Protein 3 or Stromal Cell-Derived Factor 1 Receptor or CD184 or CXCR4) - Featured News & Press Releases 102 May 25, 2016: GlycoMimetics plans to file IND application for GMI-1359 102 May 19, 2016: BioLineRx BL-8040 to be Presented at Upcoming Scientific Conferences 102 May 16, 2016: Upsher-Smith Announces Start Of First In Human Clinical Trial In Oncology With Novel CXCR4 Antagonist USL311 102 May 09, 2016: X4 Pharmaceuticals Announces Initiation of Phase 1/2 Study of X4P-001 in Patients with Advanced Clear Cell Renal Cell Carcinoma 103 Apr 19, 2016: BioLineRx Announces Presentation of Detailed Mechanism of Action Data for Lead Oncology Platform at AACR 2016 103 Apr 19, 2016: X4 Pharmaceuticals Announces Data Presentation for Lead Candidate X4P-001 at AACR Annual Meeting 104 Mar 29, 2016: BioLineRx Reports Successful Top-Line Results in Phase 2 Trial for AML 105 Mar 23, 2016: BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment 107 Mar 17, 2016: GlycoMimetics to Present New Preclinical Data on Its E-selectin-CXCR4 Dual Antagonist at AACR Annual Meeting 2016 108 Dec 14, 2015: BioLineRx Announces Regulatory Submission for Phase 2 Trial of BL-8040 as Novel Stem Cell Mobilization Treatment 108 Dec 14, 2015: X4 Pharmaceuticals Announces FDA Allowance of X4P-001 IND for Phase 1b/2a Study of in Refractory Clear Cell Renal Cell Carcinoma 109 Dec 14, 2015: X4 Pharmaceuticals Unveils Development Strategy for CXCR4 Inhibitor Pipeline in Cancer Supported by $37.5 million Series A Financing 110 Dec 07, 2015: GlycoMimetics Presents Preclinical Data at ASH Annual Meeting Showing GMI-1359 Enhances Efficacy of Chemotherapy in FLT-3 AML Model 112 Nov 23, 2015: BioLineRx Announces Initiation of Phase 1/2 Trial for Novel Treatment in Two Bone Marrow Failure Conditions 112 Nov 09, 2015: GlycoMimetics To Present Poster on GMI-1359 at at 57th Annual ASH Meeting 113 Appendix 115 Methodology 115 Coverage 115 Secondary Research 115 Primary Research 115 Expert Panel Validation 115 Contact Us 115 Disclaimer 116
List of Tables
Number of Products under Development for, H1 2016 11 Number of Products under Development by Therapy Area, H1 2016 12 Number of Products under Development by Indication, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Early Stage Products, H1 2016 17 Comparative Analysis by Unknown Stage Development, H1 2016 18 Number of Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 20 Products under Development by Companies, H1 2016 (Contd..1) 21 Products under Development by Companies, H1 2016 (Contd..2) 22 Products under Development by Companies, H1 2016 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H1 2016 24 Products under Investigation by Universities/Institutes, H1 2016 25 Assessment by Monotherapy/Combination Products, H1 2016 26 Number of Products by Stage and Mechanism of Action, H1 2016 28 Number of Products by Stage and Route of Administration, H1 2016 30 Number of Products by Stage and Molecule Type, H1 2016 32 Pipeline by AdAlta Pty Ltd., H1 2016 33 Pipeline by Ambrx, Inc., H1 2016 34 Pipeline by Anchor Therapeutics, Inc., H1 2016 35 Pipeline by Biokine Therapeutics Ltd., H1 2016 36 Pipeline by BioLineRx, Ltd., H1 2016 37 Pipeline by Bristol-Myers Squibb Company, H1 2016 38 Pipeline by Eli Lilly and Company, H1 2016 39 Pipeline by Globavir Biosciences, Inc., H1 2016 40 Pipeline by GlycoMimetics, Inc., H1 2016 41 Pipeline by NeED Pharma s.r.l., H1 2016 42 Pipeline by Pharis Biotec GmbH, H1 2016 43 Pipeline by Polyphor Ltd., H1 2016 44 Pipeline by Sanofi, H1 2016 45 Pipeline by TaiGen Biotechnology Co., Ltd., H1 2016 46 Pipeline by Upsher-Smith Laboratories, Inc., H1 2016 47 Pipeline by X4 Pharmaceuticals, Inc., H1 2016 48 Dormant Projects, H1 2016 96 Dormant Projects (Contd..1), H1 2016 97 Dormant Projects (Contd..2), H1 2016 98 Dormant Projects (Contd..3), H1 2016 99 Dormant Projects (Contd..4), H1 2016 100 Discontinued Products, H1 2016 101
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
